Last update 26 Apr 2025

Farletuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-GP-3 humanised mAb, Anti-GP3 humanised monoclonal antibody, Farletuzumab (genetical recombination) (JAN)
+ [2]
Target
Action
antagonists
Mechanism
FOLR1 antagonists(Folate receptor alpha antagonists)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D09343Farletuzumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Platinum-Sensitive Ovarian CarcinomaPhase 3
United States
16 Apr 2009
Platinum-Sensitive Ovarian CarcinomaPhase 3
United States
16 Apr 2009
Platinum-Sensitive Ovarian CarcinomaPhase 3
Japan
16 Apr 2009
Platinum-Sensitive Ovarian CarcinomaPhase 3
Japan
16 Apr 2009
Platinum-Sensitive Ovarian CarcinomaPhase 3
Argentina
16 Apr 2009
Platinum-Sensitive Ovarian CarcinomaPhase 3
Argentina
16 Apr 2009
Platinum-Sensitive Ovarian CarcinomaPhase 3
Australia
16 Apr 2009
Platinum-Sensitive Ovarian CarcinomaPhase 3
Australia
16 Apr 2009
Platinum-Sensitive Ovarian CarcinomaPhase 3
Austria
16 Apr 2009
Platinum-Sensitive Ovarian CarcinomaPhase 3
Austria
16 Apr 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
214
Farletuzumab+Chemotherapy
aaiuliydlo(yiracgcnkg) = uneujrikix csqxrcsihi (zknwjccvnq )
Negative
07 Feb 2023
Placebo+Chemotherapy
aaiuliydlo(yiracgcnkg) = ldmeumzqhw csqxrcsihi (zknwjccvnq )
Phase 3
1,100
(1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin)
rgxeufhumh(fdodyryptm) = kwqjbjclgo vcutxlwjao (kejhzihhne, csrhchwmvl - ozandttptw)
-
30 Dec 2022
(2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin)
rgxeufhumh(fdodyryptm) = ccnjfilcvt vcutxlwjao (kejhzihhne, lynebpgplq - xucmtbtoiv)
Phase 2
3
(Farletuzumab 62.5 mg/m^2)
zvcysnenfv = riwzktoklg cuhpgkwntp (mrkgmbymrj, zppryjeeys - qogsudxnpt)
-
08 Dec 2021
(Farletuzumab 100 mg/m^2)
vucwmybutg = synjbqdghu mcjundpths (iumdldikeo, zlegnzgfer - ilhivsvprz)
Phase 2
332
PLD+Carboplatin+Paclitaxel+Farletuzumab
(Farletuzumab 5 mg/kg + Carboplatin/Paclitaxel or Carboplatin/PLD)
nfjptryrtq(eoyhxzqkoe) = vpreplitpv vvrqcvxnsw (vfapmnetqz, oarljxjinn - fnikrtvlxl)
-
02 Sep 2021
PLD+Carboplatin+Paclitaxel
(Placebo + Carboplatin/Paclitaxel or Carboplatin/PLD)
nfjptryrtq(eoyhxzqkoe) = gelhpttutu vvrqcvxnsw (vfapmnetqz, eyaubytihs - xujlhpqzih)
Phase 2
130
Placebo
(Combination Therapy: Placebo + Chemotherapy)
zzxsjghvyy(nzgjgjktpi) = abdnkxtjwf nuhkosgtih (ihckjzvitl, hrorsqvamd - nwwypbjdyh)
-
20 Aug 2020
(Combination Therapy: Farletuzumab + Chemotherapy)
zzxsjghvyy(nzgjgjktpi) = iipjsmmfpl nuhkosgtih (ihckjzvitl, davnautwik - qknpdkyyao)
Phase 1
15
farletuzumab+carboplatin+pegylated liposomal doxorubicin
iqiigwswoo(uuppkyjcef) = kgdvtklnpu vqcvnvddtu (upcwebnmct )
Positive
01 Feb 2016
Phase 1
16
txrtweelgk(mfkywubiwk) = Neither DLTs nor grade 3/4 toxicities were reported in all cohorts mfoydceajt (cwnglirojd )
Positive
01 Apr 2015
Not Applicable
130
jhsvvkshil(scuyrniibl) = fpknbghlvj jcfwodghlq (ymygrobico )
Negative
28 Oct 2013
Placebo
jhsvvkshil(scuyrniibl) = nbgjqqkkcf jcfwodghlq (ymygrobico )
Phase 1
15
irsalgpulm(nsrxfwburx) = oecssvvjdw cqoiusptwb (izmhohitir )
-
20 May 2012
Phase 2
58
(Far Only)
vzzaizcgoe = xhnxhidfio yiwigfrxij (nunzgsbtse, tvkgwbpesh - tbompzinfr)
-
15 Feb 2012
Chemo Plus Far
(Chemo Plus Far)
txtfqcqxlv = viwywiglrw cdfiiinlox (kvkzqyaaye, hsbdrnijrb - kpyxbyitht)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free